Janel Corp

Janel Corp maintains a liquidity position with a current ratio of 0.74, indicating that its current liabilities exceed its current assets, which may pose a short-term liquidity risk. The company's liquidity_fpt metric suggests a moderate liquidity risk, with cash and equivalents amounting to $10.96 million, while long-term debt stands at $18.56 million. The negative net cash position, after subtracting total debt, further highlights the need for careful liquidity management. In terms of profitability, Janel Corp's return on equity (ROE) of 21.92% is significantly higher than the typical industry median for pharmaceuticals, suggesting strong returns for shareholders. However, its return on assets (ROA) of 3.31% is relatively modest, indicating that the company is not efficiently utilizing its assets to generate profit. The operating margin, calculated as operating income of $6.43 million on revenue of $207.44 million, is 3.1%, which is below the industry average for pharmaceutical firms. The company's revenue is distributed across three segments: Life Sciences, Manufacturing, and Logistics. The Life Sciences segment is the primary contributor, with a focus on monoclonal and polyclonal antibodies and diagnostic reagents. The Manufacturing segment, through Indco, produces mixing equipment, while the Logistics segment provides transportation and distribution services. However, the input data does not provide specific revenue figures for each segment, making it difficult to assess the degree of revenue concentration. Janel Corp's growth trajectory is modest, with the outlook for the current fiscal year showing a slight increase in revenue. The company's capital expenditure of -$590,000 indicates a reduction in investment in physical assets, which may signal a focus on cost control or a shift in strategic priorities. The outlook for the next fiscal year is not explicitly provided, but the company's free cash flow of $7.01 million suggests some capacity for reinvestment or shareholder returns. The risk assessment for Janel Corp highlights a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio of 0.72 is relatively low, indicating a conservative capital structure. However, the negative net cash position after subtracting total debt is a concern. The dilution risk is low, with no significant dilution sources identified in the input data. The company's recent filings and transcripts do not provide specific details on recent events that could impact its financial performance. The company's recent financial filings and transcripts do not provide specific details on recent events that could impact its financial performance. However, the absence of significant dilution sources and the low dilution risk suggest that the company is not currently under pressure to issue additional shares.